Combination drug therapies are central to modern medicine—but developing them remains inefficient, expensive, and uncertain.

Pharmaceutical teams must evaluate thousands of potential combinations with limited ability to reliably distinguish meaningful synergy from misleading signals. Traditional methods often produce conflicting results, making it difficult to prioritize the right combinations, select optimal dosing strategies, and confidently assess safety tradeoffs.

Duet Biosystems is changing how combination drug decisions are made.

Our platform is built on MuSyC (Multi-dimensional Synergy of Combinations), a patented framework that fundamentally improves how drug interactions are quantified. Unlike conventional approaches, MuSyC separates combination effects into distinct, mechanistically meaningful components—such as potency and efficacy—providing clearer, more actionable insight into how drugs work together.

We are extending this foundation with advanced machine learning and AI to help pharmaceutical teams:

Prioritize high-potential drug combinations earlier
Optimize dosing strategies with greater precision
Identify and evaluate safety tradeoffs before costly downstream studies
Reduce experimental burden and avoid low-value development paths

MuSyC has been cited in over 200 scientific publications and is under evaluation by the FDA as a Drug Development Tool, reflecting its potential to improve both internal decision-making and regulatory science.

Our mission is to become the global standard for combination drug development—enabling more confident decisions, more efficient R&D, and better outcomes for patients.

Duet Biosystems

Org chart

Teams

Offices